A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- City of Hope National Medical Center
Duarte, California, United States
- Pacific Shores Medical Group
Long Beach, California, United States
- Lac-Usc Medical Center/kenneth Norris Jr Cancer Hospital
Los Angeles, California, United States
- Moores Uc San Diego Cancer Center
San Diego, California, United States
- Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
- Georgia Regents Research Institute
Augusta, Georgia, United States
- University of Maryland Cancer Center
Baltimore, Maryland, United States
- University of Michigan Cancer Center
Ann Arbor, Michigan, United States
- Michigan State University Breslin Cancer Center
Lansing, Michigan, United States
- St Vincent Frontier Cancer Center
Billings, Montana, United States
- Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States
- Regional Cancer Center Associates, Llc
Little Silver, New Jersey, United States
- Roswell Cancer Center
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Toledo Clinic Cancer Centers
Toledo, Ohio, United States
- Tulsa Cancer Center
Tulsa, Oklahoma, United States
- Geisinger Medical Center
Danville, Pennsylvania, United States
- University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
- Houston Methodist Cancer Center
Houston, Texas, United States
- Northwest Medical Specialists & Research Institute
Puyallup, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Dec 2016
- Primary completion
- 6 Jun 2022
- Completion
- 6 Jun 2022
- Last update posted
- 15 Jun 2023
- Registered enrollment
- 33
- Registry id
- NCT02760485
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.